Implementation of the Medicare Drug Price Negotiation Program (MDPNP) under the Inflation Reduction Act began on Jan. 1, and pharmacies are now actively running claims for the first 10 negotiated drugs. While the program primarily targets brand name drugs, authorized generics for the 10 negotiated drugs are also included and must comply with the same Maximum Fair Price (MFP) requirements under the MDPNP. At this point the only drug impacted with an authorized generic is Farxiga.
A full list of all NDCs subject to MFP is included here.
NCPA
